Authors: Yamamoto, Takahito; Suzuki, Akio; Kohno, Yoshiro; Nagata, Kiyoshi; Yamazoe, Yasushi

Source: Current Drug Metabolism, Volume 7, Number 2, February 2006 , pp. 135-146(12)

Publisher: Bentham Science Publishers

Abstract:

The purpose of this study was to propose a new method to predict in vivo drug-drug interactions (DDIs) for a high clearance drug from in vitro data. As the high clearance drug, NE-100 (N, N-dipropyl-2-[4-methoxy-3-(2- phenylethoxy)phenyl]ethylamine monohydrochloride) was used. First, approach based on Iu/Ki value was used for the prediction of DDIs between NE-100 and concomitant drugs. When the Ki values (Ki-cal) obtained from the microtiter plate (MTP) assay and the reported Ki values (Ki-rep) for these drugs were used to predict increases at levels of NE-100 AUCoral (AUCoral ratio), the AUCoral ratios from the Iu /Ki-cal correlated with those from the Iu/Ki-rep. This result suggests that the Kical from the MTP assay can be used for prediction of DDIs instead of the Ki-rep value. Second, a new approach combining the inhibition rate (R) calculated from the MTP assay and two physiological models was used to predict DDIs. When the AUCoral ratios of NE-100 by various drugs were predicted using the R value and the well-stirred model, the ratios were similar to those predicted using the Iu/Ki. However, after co-administration of drugs such as quinidine, propafenone and thioridazine (potent inhibitors of CYP2D6), the NE-100 AUCoral ratios predicted from the dispersion model was much greater than those from well-stirred model. This result shows that application of the dispersion model to the prediction method using the R value might sensitively and precisely predict the increased levels of AUCoral by DDIs for high clearance drug, compared with the prediction method using Iu/Ki value.

Keywords: Drug-drug interactions; Prediction; High throughput screening; Microtiter plate assay; Dispersion model; Cytochrome P450; CYP2D6

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138920006775541570

Affiliations: 1: Drug Metabolism Laboratory, Medicinal Development Research Laboratories, Taisho Pharmaceutical Co., Ltd., 403, Yoshino-cho 1-chome, Kita-ku, Saitama-shi, Saitama 331-9530, Japan.

Publication date: 2006-02-01

More about this publication?

• Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. The journal serves as an international forum for the publication of timely reviews in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments. The journal covers the following areas:
  
  In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites and adducts.

Related content

• In this: publication
• By this: publisher
• In this Subject: Anatomy & Physiology ,  Pharmacology
• By this author: Yamamoto, Takahito ;  Suzuki, Akio ;  Kohno, Yoshiro ;  Nagata, Kiyoshi ;  Yamazoe, Yasushi

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers